ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced positive results from its ANKTIVA ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature ...

The company said that responding patients lived longer overall, with a median survival of 16.2 months. ・The data come from ...

Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through its proprietary fascin inhibitor technology, today ...

Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. The stock closed the ...

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...

ICIs combined with chemotherapy showed higher efficacy than bevacizumab in treating advanced driver gene–negative NS-NSCLC. The study reported improved PFS and OS for patients receiving ICIs compared ...

Cancer cells employ a variety of strategies to evade the immune system, and modern immunotherapies aim precisely at these ...

Please provide your email address to receive an email when new articles are posted on . People with cancer who received statins during immune checkpoint inhibitor therapy had improved prognosis.